{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:50:13Z","timestamp":1765889413034,"version":"3.38.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.amjoto.2024.104517","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:37:58Z","timestamp":1732603078000},"page":"104517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adverse events of mepolizumab in the treatment of nasal polyps: A FDA database evaluation"],"prefix":"10.1016","volume":"46","author":[{"given":"Brooke","family":"Stephanian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalena","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida Martinez","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.amjoto.2024.104517_bb0005","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.amjoto.2024.104517_bb0010","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.amjoto.2024.104517_bb0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti\u2013IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.amjoto.2024.104517_bb0025","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/coa.12189","article-title":"Quality of life and associated factors in persons with chronic rhinosinusitis in the general population: a prospective questionnaire and clinical cross\u2010sectional study","volume":"38","author":"Lange","year":"2013","journal-title":"Clinical Otolaryngology"},{"issue":"4","key":"10.1016\/j.amjoto.2024.104517_bb0030","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.amjoto.2024.104517_bb0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/0145561320964653","article-title":"The role of biologics in chronic rhinosinusitis with nasal polyps","volume":"100","author":"Patel","year":"2021","journal-title":"Ear Nose Throat J"},{"issue":"13","key":"10.1016\/j.amjoto.2024.104517_bb0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjoto.2024.104517_bb0045","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"13","key":"10.1016\/j.amjoto.2024.104517_bb0050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"9842","key":"10.1016\/j.amjoto.2024.104517_bb0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.amjoto.2024.104517_bb0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jaci.2009.11.048","article-title":"A review of treatment with mepolizumab, an anti\u2013IL-5 mAb, in hypereosinophilic syndromes and asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.amjoto.2024.104517_bb0065","unstructured":"Bah\u00e7ecio\u011flu SN, T\u00fcrk M, Atay\u0131k E, \u00c7etin GP, Arslan B, G\u00fclmez \u0130. Mepolizumab-related adverse events in severe eosinophilic asthma: a real-life study. Asthma Allergy Immunol 2022; 20: 81. 2022 Aug 1;6."},{"issue":"5","key":"10.1016\/j.amjoto.2024.104517_bb0070","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/02770903.2020.1723623","article-title":"Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety","volume":"58","author":"van Toor","year":"2021","journal-title":"J Asthma"},{"issue":"7","key":"10.1016\/j.amjoto.2024.104517_bb0075","doi-asserted-by":"crossref","first-page":"864","DOI":"10.7150\/ijms.5892","article-title":"A survey of the FAERS database concerning the adverse event profiles of \u03b11-adrenoreceptor blockers for lower urinary tract symptoms","volume":"10","author":"Yoshimura","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.amjoto.2024.104517_bb0080","unstructured":"Food and Drug Administration USA. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Accessed 1 July 2023. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"issue":"12","key":"10.1016\/j.amjoto.2024.104517_bb0085","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/lary.29992","article-title":"Dupilumab adverse events in nasal polyp treatment: analysis of FDA adverse event reporting system","volume":"132","author":"Swisher","year":"2022","journal-title":"Laryngoscope"},{"issue":"8","key":"10.1016\/j.amjoto.2024.104517_bb0090","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1159\/000514262","article-title":"Real-life experience of monoclonal antibody treatments in chronic rhinosinusitis with nasal polyposis","volume":"182","author":"Meier","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"issue":"9","key":"10.1016\/j.amjoto.2024.104517_bb0095","article-title":"Analysis of individual differences in vaccine pharmacovigilance using VAERS data and MedDRA system organ classes: a use case study with trivalent influenza vaccine","author":"Du","year":"2017","journal-title":"Biomedical Informatics Insights"},{"issue":"7","key":"10.1016\/j.amjoto.2024.104517_bb0100","article-title":"Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA","author":"Jia","year":"2019","journal-title":"PeerJ"},{"year":"2023","series-title":"R: A language and environment for statistical computing","author":"Core Team R","key":"10.1016\/j.amjoto.2024.104517_bb0105"},{"issue":"2","key":"10.1016\/j.amjoto.2024.104517_bb0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3906\/sag-1912-62","article-title":"Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilicasthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study","volume":"50","author":"Yilmaz","year":"2020","journal-title":"Turkish Journal of Medical Sciences"},{"issue":"2","key":"10.1016\/j.amjoto.2024.104517_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/19458924221149270","article-title":"Current understanding of the role of eosinophils in CRSwNP and implications for treatment with mepolizumab and benralizumab","volume":"37","author":"Carney","year":"2023","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.amjoto.2024.104517_bb0120","doi-asserted-by":"crossref","unstructured":"Desrosiers M, Diamant Z, Castelnuovo P, Hellings PW, Han JK, Peters AT, Silver J, Smith SG, Fuller A, Sousa AR, Chan RH. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up. InInternational Forum of Allergy & Rhinology 2024 Jan (Vol. 14, No. 1, pp. 18\u201331).","DOI":"10.1002\/alr.23219"},{"issue":"7","key":"10.1016\/j.amjoto.2024.104517_bb0125","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/lary.31305","article-title":"Real-world adverse events after type 2 biologic use in chronic rhinosinusitis with nasal polyps","volume":"134","author":"Dorling","year":"2024","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.amjoto.2024.104517_bb0130","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092400303X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092400303X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T01:19:18Z","timestamp":1741051158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019607092400303X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S019607092400303X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2024.104517","relation":{},"ISSN":["0196-0709"],"issn-type":[{"type":"print","value":"0196-0709"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events of mepolizumab in the treatment of nasal polyps: A FDA database evaluation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2024.104517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104517"}}